Literature DB >> 6628508

Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

H M Norbury, R A Franklin, P K Marrott, S J Warrington.   

Abstract

The pharmacokinetics of indoramin (Baratol) have been studied in five male and five female healthy, middle-aged volunteers after intravenous administration (0.14 mg/kg). Elimination occurred in an apparently biexponential fashion with a mean elimination half-life of 4.0 h (+/- 0.25 SEM). The mean plasma clearance was 19.9 ml/min/kg (+/- 1.32 SEM) and the mean volume of distribution 7.4 l/kg (+/- 0.81 SEM). There were no significant differences in these parameters between male and female volunteers. Protein binding of indoramin ranged from 85.6% at 81 ng/ml to 72.2% at 129 micrograms/ml. Two classes of binding site were evident, with affinity constants of 6.85 X 10(4)M -1 and 4.30 X 10(3)M -1.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628508     DOI: 10.1007/bf00543798

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Pharmacokinetics of oral indoramin.

Authors:  G N Volans; D Jeffereys; A N Latham; T Frost
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

3.  Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.

Authors:  A J Swaisland
Journal:  Analyst       Date:  1981-06       Impact factor: 4.616

4.  Prazosin, pharmacokinetics and concentration effect.

Authors:  D N Bateman; D C Hobbs; T M Twomey; E A Stevens; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

5.  Pharmacokinetics of prazosin in man.

Authors:  D C Hobbs; T M Twomey; R F Palmer
Journal:  J Clin Pharmacol       Date:  1978 Aug-Sep       Impact factor: 3.126

6.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

  6 in total
  7 in total

1.  The pharmacokinetics of oral indoramin during pregnancy.

Authors:  I Schabort; H J Odendaal; D M Pierce
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

2.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

6.  Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Predisposition to Graves' disease and Graves' ophthalmopathy by genetic variants of IL2RA.

Authors:  Juan Du; Xin Wang; Guiqin Tan; Wenwen Wei; Fangyu Zhou; Zhongzhi Liang; Hua Li; Hongsong Yu
Journal:  J Mol Med (Berl)       Date:  2021-07-21       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.